Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 221
Filter
2.
Diabetologia ; 56(4): 901-10, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23314847

ABSTRACT

AIMS/HYPOTHESIS: Obesity is associated with aldosterone excess, hypertension and the metabolic syndrome, but the relative contribution of aldosterone to obesity-related complications is debated. We previously demonstrated that aldosterone impairs insulin secretion, and that genetic aldosterone deficiency increases glucose-stimulated insulin secretion in vivo. We hypothesised that elimination of endogenous aldosterone would prevent obesity-induced insulin resistance and hyperglycaemia. METHODS: Wild-type and aldosterone synthase-deficient (As (-/-)) mice were fed a high-fat (HF) or normal chow diet for 12 weeks. We assessed insulin sensitivity and insulin secretion using clamp methodology and circulating plasma adipokines, and examined adipose tissue via histology. RESULTS: HF diet induced weight gain similarly in the two groups, but As (-/-) mice were protected from blood glucose elevation. HF diet impaired insulin sensitivity similarly in As (-/-) and wild-type mice, assessed by hyperinsulinaemic-euglycaemic clamps. Fasting and glucose-stimulated insulin were higher in HF-fed As (-/-) mice than in wild-type controls. Although there was no difference in insulin sensitivity during HF feeding in As (-/-) mice compared with wild-type controls, fat mass, adipocyte size and adiponectin increased, while adipose macrophage infiltration decreased. HF feeding significantly increased hepatic steatosis and triacylglycerol content in wild-type mice, which was attenuated in aldosterone-deficient mice. CONCLUSIONS/INTERPRETATION: These studies demonstrate that obesity induces insulin resistance independently of aldosterone and adipose tissue inflammation, and suggest a novel role for aldosterone in promoting obesity-induced beta cell dysfunction, hepatic steatosis and adipose tissue inflammation.


Subject(s)
Adipocytes/cytology , Aldosterone/deficiency , Hyperglycemia/chemically induced , Adiponectin/metabolism , Adipose Tissue/metabolism , Aldosterone/pharmacology , Animals , Blood Glucose/metabolism , Body Composition , Constriction, Pathologic , Diet, High-Fat , Glucose Clamp Technique , Insulin/metabolism , Insulin Resistance , Liver/pathology , Macrophages/metabolism , Male , Mice , Mice, Inbred C57BL , Random Allocation , Somatostatin/pharmacology
3.
Nat Genet ; 11(1): 76-82, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7550319

ABSTRACT

Sensitivity of blood pressure to dietary salt is a common feature in subjects with hypertension. These features are exemplified by the mendelian disorder, Liddle's syndrome, previously shown to arise from constitutive activation of the renal epithelial sodium channel due to mutation in the beta subunit of this channel. We now demonstrate that this disease can also result from a mutation truncating the carboxy terminus of the gamma subunit of this channel; this truncated subunit also activates channel activity. These findings demonstrate genetic heterogeneity of Liddle's syndrome, indicate independent roles of beta and gamma subunits in the negative regulation of channel activity, and identify a new gene in which mutation causes a salt-sensitive form of human hypertension.


Subject(s)
Hypertension/genetics , Ion Channel Gating/genetics , Sodium Channels/genetics , Sodium, Dietary/adverse effects , Adolescent , Adult , Aldosterone/deficiency , Alleles , Amino Acid Sequence , Animals , Base Sequence , Codon/genetics , Epithelial Sodium Channels , Gene Expression Regulation , Genes , Genes, Dominant , Humans , Hypertension/chemically induced , Hypertension/classification , Hypertension/metabolism , Hypokalemia/genetics , Kidney Tubules, Proximal/metabolism , Middle Aged , Molecular Sequence Data , Mutagenesis, Site-Directed , Mutation , Oocytes/metabolism , Pedigree , Rats , Recombinant Fusion Proteins/metabolism , Renin/deficiency , Sequence Alignment , Sequence Homology, Amino Acid , Sodium Channels/deficiency , Sodium Channels/physiology , Syndrome , Terminator Regions, Genetic , Xenopus laevis
4.
Pflugers Arch ; 464(4): 331-43, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22941338

ABSTRACT

Circulating aldosterone levels are increased in human pregnancy. Inadequately low aldosterone levels as present in preeclampsia, a life-threatening disease for both mother and child, are discussed to be involved in its pathogenesis or severity. Moreover, inactivating polymorphisms in the aldosterone synthase gene have been detected in preeclamptic women. Here, we used aldosterone synthase-deficient (AS(-/-)) mice to test whether the absence of aldosterone is sufficient to impair pregnancy or even to cause preeclampsia. AS(-/-) and AS(+/+) females were mated with AS(+/+) and AS(-/-) males, respectively, always generating AS(+/-) offspring. With maternal aldosterone deficiency in AS(-/-) mice, systolic blood pressure was low before and further reduced during pregnancy with no increase in proteinuria. Yet, AS(-/-) had smaller litters due to loss of fetuses as indicated by a high number of necrotic placentas with massive lymphocyte infiltrations at gestational day 18. Surviving fetuses and their placentas from AS(-/-) females were smaller. High-salt diet before and during pregnancy increased systolic blood pressure only before pregnancy in both genotypes and abolished the difference in blood pressure during late pregnancy. Litter size from AS(-/-) was slightly improved and the differences in placental and fetal weights between AS(+/+) and AS(-/-) mothers disappeared. Overall, an increased placental efficiency was observed in both groups paralleled by a normalization of elevated HIF1α levels in the AS(-/-) placentas. Our results demonstrate that aldosterone deficiency has profound adverse effects on placental function. High dietary salt intake improved placental function. In this animal model, aldosterone deficiency did not cause preeclampsia.


Subject(s)
Aldosterone/deficiency , Pregnancy Outcome , Aldosterone/physiology , Animals , Blood Pressure/drug effects , Blood Pressure/genetics , Blood Pressure/physiology , Cytochrome P-450 CYP11B2/genetics , Diet , Disease Models, Animal , Female , Fetal Death/genetics , Fetal Death/metabolism , Fetal Death/physiopathology , Fetal Growth Retardation/genetics , Fetal Growth Retardation/metabolism , Fetal Growth Retardation/physiopathology , Gestational Age , Heterozygote , Homozygote , Lymphocytes/physiology , Male , Mice , Mutation , Necrosis , Placenta/drug effects , Placenta/metabolism , Placenta/pathology , Placenta/physiopathology , Pre-Eclampsia/etiology , Pre-Eclampsia/genetics , Pregnancy , Proteinuria/genetics , Sodium Chloride/pharmacology
5.
Kidney Int ; 82(6): 619-20, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22935878

ABSTRACT

Activation of mineralocorticoid receptors (MRs) classically has been associated with electrolyte transport, but we now know that MR activation can also lead to tissue inflammation and fibrosis. Aldosterone consistently activates MR, but under selected circumstances, endogenous glucocorticoids such as cortisol and corticosterone can also trigger MR. Tissue-specific safeguards such as the enzyme 11ß-hydroxysteroid dehydrogenase limit glucocorticoid-induced MR activation, while the presence of reactive oxygen species may enhance the ability for glucocorticoid-induced MR activation even in the absence of aldosterone.


Subject(s)
Aldosterone/deficiency , Angiotensin II , Heart Diseases/prevention & control , Kidney Diseases/prevention & control , Mineralocorticoid Receptor Antagonists/pharmacology , Receptors, Mineralocorticoid/drug effects , Spironolactone/pharmacology , Vascular Diseases/prevention & control , Animals
6.
Kidney Int ; 82(6): 643-51, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22622494

ABSTRACT

Angiotensin II causes cardiovascular injury in part by aldosterone-induced mineralocorticoid receptor activation, and it can also activate the mineralocorticoid receptor in the absence of aldosterone in vitro. Here we tested whether endogenous aldosterone contributes to angiotensin II/salt-induced cardiac, vascular, and renal injury by the mineralocorticoid receptor. Aldosterone synthase knockout mice and wild-type littermates were treated with angiotensin II or vehicle plus the mineralocorticoid receptor antagonist spironolactone or regular diet while drinking 0.9% saline. Angiotensin II/salt caused hypertension in both the knockout and wild-type mice, an effect significantly blunted in the knockout mice. Either genetic aldosterone deficiency or mineralocorticoid receptor antagonism reduced cardiac hypertrophy, aortic remodeling, and albuminuria, as well as cardiac, aortic, and renal plasminogen activator inhibitor-1 mRNA expression during angiotensin II treatment. Mineralocorticoid receptor antagonism reduced angiotensin II/salt-induced glomerular hypertrophy, but aldosterone deficiency did not. Combined mineralocorticoid receptor antagonism and aldosterone deficiency reduced blood urea nitrogen and restored nephrin immunoreactivity. Angiotensin II/salt also promoted glomerular injury through the mineralocorticoid receptor in the absence of aldosterone. Thus, mineralocorticoid antagonism may have protective effects in the kidney beyond aldosterone synthase inhibition.


Subject(s)
Aldosterone/deficiency , Angiotensin II , Heart Diseases/prevention & control , Kidney Diseases/prevention & control , Mineralocorticoid Receptor Antagonists/pharmacology , Receptors, Mineralocorticoid/drug effects , Spironolactone/pharmacology , Vascular Diseases/prevention & control , Animals , Aorta/drug effects , Aorta/metabolism , Aorta/pathology , Biomarkers/blood , Biomarkers/urine , Blood Pressure/drug effects , Cytochrome P-450 CYP11B2/deficiency , Cytochrome P-450 CYP11B2/genetics , Disease Models, Animal , Fibrosis , Gene Expression Regulation , Heart Diseases/chemically induced , Heart Diseases/genetics , Heart Diseases/metabolism , Heart Diseases/pathology , Inflammation/genetics , Inflammation/metabolism , Kidney Diseases/chemically induced , Kidney Diseases/genetics , Kidney Diseases/metabolism , Kidney Diseases/pathology , Kidney Glomerulus/drug effects , Kidney Glomerulus/metabolism , Kidney Glomerulus/pathology , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Myocardium/metabolism , Myocardium/pathology , Receptors, Mineralocorticoid/metabolism , Renin-Angiotensin System/drug effects , Renin-Angiotensin System/genetics , Sodium Chloride, Dietary , Time Factors , Vascular Diseases/chemically induced , Vascular Diseases/genetics , Vascular Diseases/metabolism , Vascular Diseases/pathology
7.
Ann Biol Clin (Paris) ; 69(4): 405-10, 2011.
Article in French | MEDLINE | ID: mdl-21896404

ABSTRACT

Renal tubular acidosis (RTA) is a tubulopathy characterized by metabolic acidosis with normal anion gap secondary to abnormalities of renal acidification. RTA can be classified into four main subtypes: distal RTA, proximal RTA, combined proximal and distal RTA, and hyperkalemic RTA. Distal RTA (type 1) is caused by the defect of H(+) secretion in the distal tubules and is characterized by the inability to acidify the urine below pH 5.5 during systemic acidemia. Proximal RTA (type 2) is caused by an impairment of bicarbonate reabsorption in the proximal tubules and characterized by a decreased renal bicarbonate threshold. Combined proximal and distal RTA (type 3) secondary to a reduction in tubular reclamation of bicarbonate and an inability to acidify the urine in the face of severe acidemia. Hyperkalemic RTA (type 4) may occur as a result of aldosterone deficiency or tubular insensitivity to aldosterone. Clinicians should be alert to the presence of RTA in patients with an unexplained normal anion gap acidosis, hypokalemia, recurrent nephrolithiasis and nephrocalcinosis. The mainstay of treatment of RTA remains alkali replacement.


Subject(s)
Acidosis, Renal Tubular/metabolism , Acid-Base Equilibrium , Acidosis, Renal Tubular/classification , Acidosis, Renal Tubular/drug therapy , Aldosterone/deficiency , Anion Exchange Protein 1, Erythrocyte/metabolism , Humans , Hypercalciuria/metabolism , Hyperkalemia/metabolism , Hypokalemia/metabolism , Nephrocalcinosis/metabolism , Sodium Bicarbonate/therapeutic use , Treatment Outcome , Vacuolar Proton-Translocating ATPases/metabolism
8.
Am J Physiol Regul Integr Comp Physiol ; 299(4): R1013-9, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20686175

ABSTRACT

The cardiovascular system is under the control of the circadian clock, and disturbed circadian rhythms can induce cardiovascular pathologies. This cyclic regulation is probably brought about by the circadian expression of genes encoding enzymes and regulators involved in cardiovascular functions. We have previously shown that the rhythmic transcription of output genes is, in part, regulated by the clock-controlled PAR bZip transcription factors DBP (albumin D-site binding protein), HLF (hepatic leukemia factor), and TEF (thyrotroph embryonic factor). The simultaneous deletion of all three PAR bZip transcription factors leads to increased morbidity and shortened life span. In the present study, we demonstrate that Dbp/Tef/Hlf triple knockout mice develop cardiac hypertrophy and left ventricular dysfunction associated with a low blood pressure. These dysfunctions are exacerbated by an abnormal response to this low blood pressure characterized by low aldosterone levels. The phenotype of PAR bZip knockout mice highlights the importance of circadian regulators in the modulation of cardiovascular functions.


Subject(s)
Aldosterone/deficiency , Basic-Leucine Zipper Transcription Factors/genetics , Cardiomegaly/genetics , Circadian Rhythm/genetics , DNA-Binding Proteins/genetics , Hypotension/genetics , Transcription Factors/genetics , Adrenergic beta-Antagonists/pharmacology , Animals , Atenolol/pharmacology , Basic-Leucine Zipper Transcription Factors/physiology , Blood Pressure/physiology , Cardiomegaly/pathology , Cardiovascular Physiological Phenomena , Circadian Rhythm/physiology , DNA-Binding Proteins/physiology , Epithelial Sodium Channels/metabolism , Heart Rate/physiology , Kidney/physiology , Male , Mice , Mice, Knockout , Phenotype , Sympathetic Nervous System/physiology , Transcription Factors/physiology
9.
Nihon Jinzo Gakkai Shi ; 52(1): 80-5, 2010.
Article in Japanese | MEDLINE | ID: mdl-20166546

ABSTRACT

Although hypokalemia is a common clinical problem, symptoms generally do not become manifest unless the serum potassium (K) falls rapidly. We encountered five cases with symptomatic severe hypokalemia (K<2.0 mEq/L) hospitalized for the past 15 months at our hospital. We examined the clinical characteristics and treatment of these patients. All five patients were women, and their mean age was 77.8 (73-82)years. They suffered from hypertension. Mean K level at admission was 1.66 (1.4-1.9) mEq/L and HCO3(-) was 48.3 (33.6-56.1) mmol/L. Plasma aldosterone level was low and plasma rennin activity was suppressed. All patients developed progressive muscle weakness with elevated creatinine phosphokinase. Three of the patients had received Chinese medicine which contained licorice, one received glycyrrhizin and the other one had received both. We diagnosed these cases as pseudoaldosteronism induced by glycyrrhizin. With discontinuation of the drugs and intravenous as well as oral K supplementation, serum K were normalized and clinical symptoms improved within 12 days. For one patient who developed cardiac dysfunction, concentrated K solution (230 mEq/L) was infused into the central vein. These findings show that glycyrrhizin ingestion should be kept in mind as a cause of an extreme degree of an hypokalemia, especially in elderly patients.


Subject(s)
Anti-Inflammatory Agents/adverse effects , Drugs, Chinese Herbal/adverse effects , Glycyrrhizic Acid/adverse effects , Hypokalemia/chemically induced , Rhabdomyolysis/chemically induced , Aged , Aged, 80 and over , Aldosterone/blood , Aldosterone/deficiency , Alkalosis , Drugs, Chinese Herbal/chemistry , Female , Humans , Hypertension , Hypokalemia/drug therapy , Phytotherapy/adverse effects , Potassium/administration & dosage , Renin/blood , Renin/deficiency , Severity of Illness Index , Therapeutics
10.
J Pediatr Endocrinol Metab ; 33(11): 1501-1505, 2020 Nov 26.
Article in English | MEDLINE | ID: mdl-32809961

ABSTRACT

Background Aldosterone deficiency (hypoaldosteronism) or aldosterone resistance (pseudohypoaldosteronism) both result in defective aldosterone activity. Case presentation A 42-day-old man presented with failure to thrive, hyponatremia, high urine sodium output, severe hyperkalemia and high plasma renin activity and aldosterone levels. NR3C2, SCNN1A, B and G sequencing showed no variants. Exclusive sodium supplementation resulted in clinical stabilization and growth normalization. His younger sibling had similar clinical and laboratory features, except for low-normal aldosterone. Both patients showed compound heterozygous mutations in CYP11B2 (c.C554T/2802pbE1-E2del). The younger patient needed transient fludrocortisone treatment and higher sodium supplementation, recuperating his weight and a normal growth velocity, although below his brother's and target height (c.10th vs. c.50th). Conclusions On a suggestive clinical picture, high aldosterone plasma levels in early infancy do not rule out aldosterone insufficiency and might mislead differential diagnosis with pseudohypoaldosteronism. Therapeutic requests and growth impairment in hypoaldosteronism vary even with a common genetic background.


Subject(s)
Aldosterone/blood , Hypoaldosteronism/diagnosis , Pseudohypoaldosteronism/diagnosis , Aldosterone/deficiency , Child , Child Development/physiology , Child, Preschool , Cytochrome P-450 CYP11B2/genetics , Diagnosis, Differential , Follow-Up Studies , Growth Charts , Humans , Hypoaldosteronism/blood , Hypoaldosteronism/genetics , Infant , Male , Mutation , Pseudohypoaldosteronism/blood , Pseudohypoaldosteronism/genetics , Siblings , Spain
11.
Steroids ; 74(4-5): 456-62, 2009.
Article in English | MEDLINE | ID: mdl-19162057

ABSTRACT

BACKGROUND: Clinical studies have established aldosterone as a critical physiological and pathophysiological factor in salt and water homeostasis, blood pressure control and in heart failure. Genetic and physiological studies of mice are used to model these processes. A sensitive and specific assay for aldosterone is therefore needed to monitor adrenocortical activity in murine studies of renal function and cardiovascular diseases. METHODS: Antibodies against aldosterone were raised in sheep as previously described. HRP-Donkey-anti-sheep IgG enzyme tracer was produced in our laboratory using the Lightning-Link HRP technique. Aldosterone ELISA protocol was validated and optimised to achieve the best sensitivity. The assay was validated by analysing the urine of mice collected under various experimental conditions designed to stimulate or suppress aldosterone in the presence of other potentially interfering steroid hormones. RESULTS: Cross-reactivity with the steroids most likely to interfere was minimal: corticosterone=0.0028%, cortisol=0.0006%, DOC=0.0048% except for 5alpha-dihydro-aldosterone=1.65%. Minimum detection limit of this ELISA was 5.2 pmole/L (1.5 pg/mL). The validity of urinary aldosterone ELISA was confirmed by the excellent correlation between results obtained before and after solvent extraction and HPLC separation step (Y=1.092X+0.03, R(2)=0.995, n=54). Accuracy studies, parallelism and imprecision data were determined and all found to be satisfactory. Using this assay, mean urinary aldosterone levels were (i) approximately 60-fold higher in females than males mice; (ii) increased 6-fold by dietary sodium restriction; (iii) increased 10-fold by ACTH infusion and (iv) reduced by >60% in Cyp11b1 null mice. CONCLUSION: We describe an ELISA for urinary aldosterone that is suitable for repeated non-invasive measurements in mice. Female aldosterone levels are higher than males. Unlike humans, most aldosterone in mouse urine is not conjugated. Increased levels were noted in response to dietary sodium restriction and ACTH treatment. The sensitivity of the assay is sufficient to detect suppressed levels in mouse models of congenital adrenal hyperplasia.


Subject(s)
Adrenal Gland Diseases/urine , Aldosterone/deficiency , Aldosterone/urine , Enzyme-Linked Immunosorbent Assay/methods , Aldosterone/metabolism , Animals , Chromatography, High Pressure Liquid , Cross Reactions/drug effects , Female , Infusion Pumps , Male , Mice , Radioimmunoassay , Reference Standards , Reproducibility of Results , Sensitivity and Specificity , Sodium Chloride, Dietary/pharmacology
12.
Endocr Dev ; 13: 133-144, 2008.
Article in English | MEDLINE | ID: mdl-18493138

ABSTRACT

Adrenal aldosterone production, the major regulator of salt and water retention, is discussed with respect to hypertensive diseases. Physiological aldosterone production is tightly regulated, either stimulated or inhibited, in the adrenal zona glomerulosa by both circulating factors and/or by locally derived endothelial factors. Arterial hypertension caused by volume overload is the leading clinical symptom indicating increased mineralocorticoid hormones. Excessive aldosterone production is seen in adenomatous disease of the adrenals. The balance between stimulatory/proliferative and antagonistic signaling is disturbed by expression of altered receptor subtypes in the adenomas. Increased aldosterone production without a detectable adenoma is the most frequent form of primary aldosteronism. Both increased sensitivity to agonistic signals and activating polymorphisms within the aldosterone synthase gene (CYP11B2) have been associated with excessive aldosterone production. 17alpha-Hydroxylase deficiency and glucocorticoidremediable aldosteronism can also cause excessive mineralocorticoid synthesis. In contrast, the severe form of pregnancy-induced hypertension, preeclampsia, is characterized by a compromised volume expansion in the presence of inappropriately low aldosterone levels. Initial evidence suggests that compromised CYP11B2 is causative, and that administration of NaCl lowered blood pressure in pregnant patients with low aldosterone availability due to a loss of function.


Subject(s)
Adrenal Glands/metabolism , Hypertension/etiology , Steroids/biosynthesis , Steroids/physiology , Adrenal Glands/physiology , Aldosterone/biosynthesis , Aldosterone/deficiency , Aldosterone/physiology , Animals , Blood Pressure/physiology , Female , Humans , Hyperaldosteronism/etiology , Hyperaldosteronism/metabolism , Hyperaldosteronism/physiopathology , Hypertension/metabolism , Hypertension, Pregnancy-Induced/etiology , Mineralocorticoids/biosynthesis , Pregnancy
13.
Adv Chronic Kidney Dis ; 25(4): 321-333, 2018 07.
Article in English | MEDLINE | ID: mdl-30139459

ABSTRACT

In contrast to distal type I or classic renal tubular acidosis (RTA) that is associated with hypokalemia, hyperkalemic forms of RTA also occur usually in the setting of mild-to-moderate CKD. Two pathogenic types of hyperkalemic metabolic acidosis are frequently encountered in adults with underlying CKD. One type, which corresponds to some extent to the animal model of selective aldosterone deficiency (SAD) created experimentally by adrenalectomy and glucocorticoid replacement, is manifested in humans by low plasma and urinary aldosterone levels, reduced ammonium excretion, and preserved ability to lower urine pH below 5.5. This type of hyperkalemic RTA is also referred to as type IV RTA. It should be noted that the mere deficiency of aldosterone when glomerular filtration rate is completely normal only causes a modest decline in plasma bicarbonate which emphasizes the importance of reduced glomerular filtration rate in the development of the hyperchloremic metabolic acidosis associated with SAD. Another type of hyperkalemic RTA distinctive from SAD in which plasma aldosterone is not reduced is referred to as hyperkalemic distal renal tubular acidosis because urine pH cannot be reduced despite acidemia or after provocative tests aimed at increasing sodium-dependent distal acidification such as the administration of sodium sulfate or loop diuretics with or without concurrent mineralocorticoid administration. This type of hyperkalemic RTA (also referred to as voltage-dependent distal renal tubular acidosis) has been best described in patients with obstructive uropathy and resembles the impairment in both hydrogen ion and potassium secretion that are induced experimentally by urinary tract obstruction and when sodium transport in the cortical collecting tubule is blocked by amiloride.


Subject(s)
Acidosis, Renal Tubular/physiopathology , Aldosterone/deficiency , Hyperkalemia/etiology , Pseudohypoaldosteronism/genetics , Ureteral Obstruction/physiopathology , Acidosis, Renal Tubular/complications , Aldosterone/metabolism , Animals , Epithelial Sodium Channels/metabolism , Humans , Hydrogen-Ion Concentration , Membrane Potentials , Nephrons/pathology , Potassium/urine , Renal Insufficiency, Chronic/complications , Sodium/metabolism
14.
J Clin Invest ; 82(5): 1624-32, 1988 Nov.
Article in English | MEDLINE | ID: mdl-3183058

ABSTRACT

Mineralocorticoid plays a role in urinary acidification and acid-base balance, but the response of the inner medulla to aldosterone has not been elucidated. A model of selective aldosterone deficiency (SAD) with hyperkalemia and hyperchloremic metabolic acidosis was employed to assess segmental acidification by measuring in situ pH, titratable acidity (TA) and total ammonia (Am). Hydrogen ion secretion was also examined as a function of the increment in in situ PCO2 in the collecting duct during bicarbonate loading. SAD rats were compared to ADX controls that received adrenalectomy and chronic replacement of gluco- and mineralocorticoid and to rats with chronic metabolic acidosis induced by oral NH4Cl (CMA). Both fractional and absolute delivery of Am to the loop of Henle was lower in SAD vs. CMA rats (1.34 to 3.63 mM, P less than 0.01). Delivery of Am to the base and tip collecting duct (BCD and TCD) was also markedly lower in SAD (1.50 vs. 0.52 and 1.77 vs. 0.47 mM, respectively, P less than 0.01). Net addition of Am and net acid between BCD and TCD, observed in CMA rats, was not observed in SAD despite equivalent degrees of systemic metabolic acidosis. Similarly, the concentration gradient favoring transfer of NH3 between loop of Henle and CD was reduced in SAD. During bicarbonate loading the increment in PCO2 at BCD, TCD and in final urine was significantly lower in SAD rats than in adrenal intact bicarbonate-loaded rats. Therefore, the acidification defect in this model of SAD appears to be a result of a decrease in ammonia production and delivery to the loop of Henle, impaired transfer from loop to collecting duct and reduction in the rate of H+ secretion by the collecting duct.


Subject(s)
Acid-Base Equilibrium , Aldosterone/deficiency , Kidney Medulla/physiopathology , Nephrons/physiopathology , Acidosis/physiopathology , Aldosterone/pharmacology , Ammonia/analysis , Animals , Bicarbonates/pharmacology , Chlorides/blood , Dexamethasone/pharmacology , Electrolytes/urine , Hyperkalemia/complications , Loop of Henle/physiopathology , Rats , Rats, Mutant Strains
15.
J Pediatr Endocrinol Metab ; 19(5): 765-70, 2006 May.
Article in English | MEDLINE | ID: mdl-16789645

ABSTRACT

We report on the first Chinese patient with triple-A syndrome, who presented at 22 months with status epilepticus secondary to hyponatraemia and hypoglycaemia. Subsequent endocrine investigations confirmed primary adrenal insufficiency and aldosterone deficiency. In the presence of achalasia and alacrima, this patient satisfies the diagnostic criteria of triple-A syndrome. Further molecular testing detected compound heterozygous mutations in the AAAS gene: a c.580C --> T transition in exon 7 and a c.771delG single nucleotide deletion in exon 8. Testing of parents and brother confirmed their heterozygous carrier status.


Subject(s)
Nuclear Pore Complex Proteins/genetics , Adrenal Cortex Diseases/complications , Adrenal Cortex Function Tests , Aldosterone/deficiency , China , Epilepsy, Tonic-Clonic/complications , Epilepsy, Tonic-Clonic/genetics , Exons/genetics , Humans , Hypoglycemia/complications , Hyponatremia/complications , Infant, Newborn , Male , Mutation/genetics , Nerve Tissue Proteins , Status Epilepticus/etiology , Syndrome
16.
Arch Intern Med ; 146(5): 996-7, 1986 May.
Article in English | MEDLINE | ID: mdl-3008682

ABSTRACT

A 60-year-old man presented with loss of weight and appetite, eosinophilia, and hyperkalemia consistent with a diagnosis of Addison's disease. Adrenal responsiveness to exogenous corticotropin was normal, but endogenous corticotropin and cortisol responses to insulin-induced hypoglycemia were both absent. Pituitary function was otherwise intact. Renin and aldosterone levels were subnormal and did not respond to postural change. To our knowledge, this is the first reported case of isolated corticotropin deficiency and hyporeninemic hypoaldosteronism together mimicking primary adrenocortical failure.


Subject(s)
Addison Disease/diagnosis , Adrenocorticotropic Hormone/deficiency , Aldosterone/deficiency , Renin/deficiency , Addison Disease/etiology , Adrenal Insufficiency/diagnosis , Diagnosis, Differential , Humans , Male , Middle Aged
17.
Arch Intern Med ; 146(12): 2407-8, 1986 Dec.
Article in English | MEDLINE | ID: mdl-3535721

ABSTRACT

A patient with cirrhosis and coexistent hyporeninemic hypoaldosteronism secondary to diabetic nephropathy rapidly formed ascites despite marked reductions in plasma aldosterone concentration and urinary aldosterone excretion. To my knowledge, this association has not been previously reported. This case supports the concept that hyperaldosteronism is not a necessary component of the salt retention of advanced liver disease. Furthermore, it suggests that certain renal disorders should be considered in cases of cirrhosis and ascites with decreased plasma renin activity.


Subject(s)
Aldosterone/deficiency , Ascites/complications , Liver Cirrhosis/complications , Renin/blood , Ascites/etiology , Diabetic Nephropathies/complications , Female , Humans , Liver Cirrhosis/etiology , Middle Aged
18.
Arch Intern Med ; 136(10): 1179-80, 1976 Oct.
Article in English | MEDLINE | ID: mdl-971018

ABSTRACT

We describe a 52-year-old man who, following the discontinuation of massive intake of sodium bicarbonate, in the absence of renal insufficiency, developed progressive hyperkalemia and hyponatremia in association with hyporeninemic hypoaldosteronism. The mechanism of this syndrome is not known, but may involve suppression of the renin-angiotensin-aldosterone axis by chronic volume expansion.


Subject(s)
Aldosterone/deficiency , Bicarbonates/adverse effects , Renin/deficiency , Aldosterone/blood , Dose-Response Relationship, Drug , Dyspnea/chemically induced , Humans , Hyperkalemia/blood , Hyponatremia/blood , Kidney Function Tests , Male , Middle Aged , Potassium/blood , Renin/blood , Sodium/blood , Substance-Related Disorders
19.
Arch Intern Med ; 137(7): 852-5, 1977 Jul.
Article in English | MEDLINE | ID: mdl-879919

ABSTRACT

The changes in plasma renin activity (PRA) and plasma aldosterone concentration (PA) in response to postural stimuli were evaluated in 12 patients with stable diabetes mellitus and in five volunteers. Seven diabetic patients had hyperkalemia, and several had renal insufficiency and neurological complications. Five diabetics and had normal serum potassium concentration, a mean creatinine clearance within the normal range, and few complications. PRA and PA were measured in these patients and in the control subjects, all of whom were receiving a diet containing 10 mEq of sodium and 50 mEq of potassium while they were in a supine position, after they were tilted to a 90 degrees position, and after upright posture for two hours. The results indicate that impaired responsiveness of PRA and PA may occur in patients with complicated and those with uncomplicated diabetes and may be responsible in part for a relatively high prevalence of hyperkalemia especially in those diabetic patients with reduced renal function.


Subject(s)
Aldosterone/deficiency , Diabetes Complications , Renin/deficiency , Adult , Aldosterone/blood , Blood Pressure , Diabetes Mellitus/metabolism , Female , Humans , Hyperkalemia/complications , Hyperkalemia/metabolism , Male , Middle Aged , Posture , Renin/blood
20.
Arch Intern Med ; 145(7): 1306-7, 1985 Jul.
Article in English | MEDLINE | ID: mdl-4015282

ABSTRACT

A patient with chronic renal failure, a strong history of moonshine abuse, and excessive urinary lead excretion had clinical and laboratory measurements compatible with combined hyperkalemic distal renal tubular acidosis and the syndrome of selective aldosterone deficiency. Extended treatment with fludrocortisone acetate, 0.1 to 0.2 mg/day, did not ameliorate acidosis or restore potassium excretion.


Subject(s)
Acidosis, Renal Tubular/complications , Aldosterone/deficiency , Hyperkalemia/complications , Lead Poisoning/complications , Acetazolamide/therapeutic use , Acidosis, Renal Tubular/drug therapy , Acidosis, Renal Tubular/physiopathology , Electrolytes/blood , Female , Fludrocortisone/therapeutic use , Furosemide/therapeutic use , Humans , Hyperkalemia/drug therapy , Hyperkalemia/physiopathology , Lead Poisoning/urine , Middle Aged , Patient Readmission
SELECTION OF CITATIONS
SEARCH DETAIL